Skip to content
AnalystLens

JOHNSON & JOHNSON 8-K Report, Corporate Update (May 17, 2024)

Reports
Other Events
Filing Date
Filed May 17, 2024
Period End
May 17, 2024
Security
JNJ
In the record · 2016–202610-K1110-Q338-K134

JNJ filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Restructuring8-K · Apr ’18Apr ’18
  2. Leadership change8-K · Dec ’20Dec ’20
  3. Deal closed8-K · Dec ’22Dec ’22
  4. Leadership change8-K · Aug ’26Aug ’26

01—Abstract

Summary

Summary of the 8-K filed May 17, 2024. Cited figures are marked; the original filing is the authoritative source.

Johnson & Johnson (JNJ) has finalized its divestiture of its remaining stake in its former Consumer Health business, now operating as Kenvue Inc. The company announced on May 17, 2024, that it completed a Debt-for-Equity Exchange.

In this transaction, JNJ exchanged its remaining 182.3 million shares of Kenvue Common Stock for $3.6 billiona aggregate principal amount of commercial paper that it had issued on May 15, 2024. This exchange effectively settles the commercial paper and marks the complete exit of Johnson & Johnson from its ownership of Kenvue. This strategic move concludes Johnson & Johnson's long-planned separation of its consumer health division.

The initial separation began with Kenvue's IPO in May 2023, followed by a significant exchange offer in August 2023 that reduced JNJ's stake substantially. The final exchange of shares for debt removes any lingering ownership ties and allows Johnson & Johnson to fully focus on its pharmaceutical and medtech segments. Investors should view this as a significant step in JNJ's strategic realignment.

02—Key points

Key Highlights

  1. Johnson & Johnson (JNJ) has completed the divestiture of its entire remaining stake in Kenvue Inc.
  2. The final separation was achieved through a Debt-for-Equity Exchange completed on May 17, 2024.
  3. JNJ exchanged 182,329,550 shares of Kenvue Common Stock for $3.6 billion of its own commercial paper.
  4. The $3.6 billion in commercial paper was issued on May 15, 2024, with net proceeds intended for general corporate purposes.
  5. Upon completion of the exchange, the commercial paper was satisfied and discharged.
  6. Johnson & Johnson no longer owns any shares of Kenvue Common Stock, marking a full exit from the consumer health business.

03—Questions

Frequently Asked Questions

  1. What is the significance of the Debt-for-Equity Exchange for Johnson & Johnson?

    The Debt-for-Equity Exchange signifies the complete separation of Johnson & Johnson from its former Consumer Health business, now Kenvue Inc. This allows JNJ to fully focus on its core Pharmaceutical and MedTech segments and simplifies its corporate structure.

  2. What was the total value of the shares exchanged?

    Johnson & Johnson exchanged 182,329,550 shares of Kenvue Common Stock. These shares were effectively used to satisfy and discharge $3.6 billion aggregate principal amount of commercial paper that JNJ had issued.

  3. What was the initial IPO price of Kenvue?

    Kenvue completed its initial public offering on May 8, 2023, at a price of $22.00 per share.

  4. How did Johnson & Johnson's ownership of Kenvue decrease over time?

    Johnson & Johnson initially owned approximately 89.6% of Kenvue after its IPO. This was reduced to about 9.5% after an exchange offer in August 2023. The final disposition occurred on May 17, 2024, through the Debt-for-Equity Exchange, leaving JNJ with 0% ownership of Kenvue.

04—Continue

← View all 8-K filings